



| Report Number: | 22-008818/D006.R000 |
|-----------------|---------------------|
| Report Date: | 08/02/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 07/26/22 12:43 |

_ _ _ _ _ _

| Customer: | IHC LLC |
|-------------------|--------------------|
| Product identity: | 010307LIRBDR200_PP |
| Client/Metrc ID: | |
| Laboratory ID: | 22-008818-0003 |

Summary

| Analyte | Result (%) | | | |
|---------|------------|--|-----------------|------------------------|
| CBN | 37.3 | • CBN | CBD-Total | 19.4% |
| ∆8-THC | 29.7 | Δ8-THC | | |
| CBD-A | 12.0 | CBD-A | THC-Total | <loq< td=""></loq<> |
| CBD | 8.91 | • CBD | | |
| CBDV-A | 0.183 | CBDV-ACBG-A | (Reported in pe | rcent of total sample) |
| CBG-A | 0.143 | CBG-A CBT | | |
| CBT | 0.140 | • CBC | | |
| CBC | 0.112 | CBDV | | |
| CBDV | 0.0741 | | | |

Page 1 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430



IHC LLC

.

No 13.8 °C

julien

825 NW 16th Ave Portland Oregon 97209

22-008818-0003

United States of America (USA)

010307LIRBDR200_PP

Customer:

Product identity: Client/Metrc ID:

Sample Date:

Laboratory ID:

Temp:

Evidence of Cooling:

Relinquished by:

12423 NE Whitaker Way Portland, OR 97230 503-254-1794



| Report Number: | 22-008818/D006.R000 |
|-----------------|---------------------|
| Report Date: | 08/02/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 07/26/22 12:43 |



Sample Results

| Potency | Method: J AOAC 20 ⁻ | 5 V98-6 (mod) ^p Unit | s % Batch: 2206386 | Analyze: 7/28/22 5:16:00 PM |
|--------------------|--------------------------------|---------------------------------|----------------------------------|-----------------------------|
| Analyte | As Dry | LOQ Notes | | |
| | Received weig | | | CBN |
| CBC | 0.112 | 0.0727 | | Δ8-THC |
| CBC-A | < LOQ | 0.0727 | | CBD-A |
| CBC-Total | < LOQ | 0.136 | | O CBD |
| CBD | 8.91 | 0.0727 | | CBDV-A |
| CBD-A | 12.0 | 0.0727 | | • CBG-A |
| CBD-Total | 19.4 | 0.136 | | СВТ |
| CBDV | 0.0741 | 0.0727 | | • CBC |
| CBDV-A | 0.183 | 0.0727 | | • CBDV |
| CBDV-Total | 0.233 | 0.136 | | |
| CBE | < LOQ | 0.0727 | | |
| CBG | < LOQ | 0.0727 | | |
| CBG-A | 0.143 | 0.0727 | | |
| CBG-Total | < LOQ | 0.136 | | |
| CBL | < LOQ | 0.0727 | | |
| CBL-A | < LOQ | 0.0727 | | |
| CBL-Total | < LOQ | 0.136 | | |
| CBN | 37.3 | 0.727 | | |
| CBT | 0.140 | 0.0727 | | |
| ∆8-THC | 29.7 | 0.727 | | |
| ∆8-THCV | < LOQ | 0.0727 | | |
| ∆9-THC | < LOQ | 0.0727 | | |
| exo-THC | < LOQ | 0.0727 | | |
| THC-A | < LOQ | 0.0727 | | |
| THC-Total | < LOQ | 0.136 | | |
| THCV | < LOQ | 0.0727 | | |
| THCV-A | < LOQ | 0.0727 | | |
| THCV-Total | < LOQ | 0.136 | | |
| Total Cannabinoids | 88.6 | | | |

www.columbialaboratories.com

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.





Report Number: 22-008818/D006.R000 **Report Date:** 08/02/2022 **ORELAP#:** OR100028 Purchase Order: **Received:** 07/26/22 12:43

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

^b = ISO/IEC 17025:2017 accredited method.

Units of Measure

% = Percentage of sample

% wt = $\mu g/g$ divided by 10,000

Approved Signatory

Derrick Tanner General Manager

www.columbialaboratories.com

Page 3 of 8

Test results relate only to the parameters tested and to the samples as received by the requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made





| Report Number: | 22-008818/D006.R000 |
|-----------------|---------------------|
| Report Date: | 08/02/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 07/26/22 12:43 |

olumbia ABORATORIES A Altertamas Company

Hemp / Cannabis Usable / Extract / Finished Products Chain of Custody Record

Revision: 4.00 Controlit: CP023 Rev 02/34/2031 EP: 03/04/2021 ORD.4PID-06020208

| | | | | | | × | inalys | is Nog | usste | el : | | | | 14 | American | |
|--|-----------------------|-------------------|------------------------------------|--------|-------------------------|--------------------|----------|-------------------------|-------------------------------|-----------|------------|------------|--|---|-------------------|-----------------|
| Company: The Hemp Collect Content kyle@thehempcollect.co Street 431 NW Flanders st. Dry: Portland State OR Day D time! Results: dropbox (IHC) Ph: (610.6081643D fx Results: [] Sting (I afferent joel@thehempcolle | 97209 | - OR 52 compounds | atrick Mult Readue - 373 perpendia | | tester schul Schertu | i & Wotes Autority | | Alexa : Vesael and Medd | pro: £.ColiumETstal Colliform | ey Metter | | | Project Number: Project Name: Custom Reporting: Report to State : [] METRC or [] Other: Tumenound time: [] S Business Day Systemater'] 3 Business Day Systemater' [] 2 Societies Day Systemater' https://www.senses.com/ | | | |
| dient Semple Identification | Dute | Three | Periodia | Future | Putany | Particular | Medition | Twant | Micro V | Mirros I. | Methods Md | Mycottodra | in the second | Sample Tear | Waldes [User0] | Converts/Mepulb |
| 09WSS200_3 | | - | - | - | x | - | _ | _ | _ | | _ | | _ | | | |
| 010307LIRBDR200_0 | and the second second | - | - | _ | X. | _ | _ | _ | - | _ | | | | | | |
| 010307LIRBDR200_PP | <u> </u> | | _ | | X | L | | | | | | | | | | |
| 0103FTS100_BK_Phil | | | | | Χ. | | | | | | | | | | | |
| 0103FTS100_SL_RSP | D | | | | x | | | | | | | | | | | |
| 0103FTS100_SH_RSP | D | | | | Χ. | | | | | | | | | | | |
| 0103FTS100_SuzieG | | | | | x | | | | | | | | | | | |
| | - | - | - | - | | | _ | - | - | | | _ | | _ | | |
| 0 | | | | - | | | - | | | - | | | - | - | | |
| Evelingustveri Byr. | E sta | Time | | 15 | R | en ad | P/ | 1 | 1 | (Da | | Th | n# | 1 Berlin | | Tak Use Only |
| yle Farook | 7/28 | 12:15 | | * | 9 | - | - | | | 7/2 | 6 | 院 | 6 | D Shisped Via ar D Clerit tinto Evidence of topping: D Yes D No - Temp (*Ct | | |
| to- | 7ns | 12743 | | P | Ų | | | | | | | | | Serepta in good condition: D Yes D No D Cash D Check D CC D Nee Prekaj storage | | |

oph in Jaconskippin mich also canners an west service principal with the COX. By engine "Relaymouth by " p Sergion advenuel to Columno Edwarteries with scrateginger tion at appointers de cares Pr (603) 254-3794 (Pao (683) 254-3462

13423 NE Wheelow Way Periland, DR (V318

whether has been a state of the state of the

Page_____of_____

opening in these is

www.columbialaboratories.com

Page 4 of 8

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.





| Report Number: | 22-008818/D006.R000 |
|-----------------|---------------------|
| Report Date: | 08/02/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 07/26/22 12:43 |

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| | | | Lai | orator | Quality Cor | ntrol Resu | ilts | | | |
|---------------------------|-----------------------------------|--------|--------|--------|-------------|------------|-------|------------|-------|--|
| J AOAC 2015 V98-6 | AOAC 2015 V98-6 Batch ID: 2206386 | | | | | | | | | |
| Laboratory Control Sample | | | | | | | | | | |
| Analyte | LCS | Result | Spike | Units | % Rec | Liı | mits | Evaluation | Notes | |
| CBDVA | 1 | 0.101 | 0.100 | % | 101 | 80.0 | - 120 | Acceptable | | |
| CBDV | 1 | 0.111 | 0.100 | % | 111 | 80.0 | - 120 | Acceptable | | |
| CBE | 1 | 0.100 | 0.100 | % | 100 | 80.0 | - 120 | Acceptable | | |
| CBDA | 1 | 0.0999 | 0.0961 | % | 104 | 90.0 | - 110 | Acceptable | | |
| CBGA | 1 | 0.0978 | 0.0942 | % | 104 | 80.0 | - 120 | Acceptable | | |
| CBG | 1 | 0.107 | 0.104 | % | 103 | 80.0 | - 120 | Acceptable | | |
| CBD | 1 | 0.117 | 0.112 | % | 104 | 90.0 | - 110 | Acceptable | | |
| THCV | 1 | 0.0998 | 0.100 | % | 99.8 | 80.0 | - 120 | Acceptable | | |
| d8THCV | 1 | 0.101 | 0.100 | % | 101 | 80.0 | - 120 | Acceptable | | |
| THCVA | 1 | 0.0949 | 0.100 | % | 94.9 | 80.0 | - 120 | Acceptable | | |
| CBN | 1 | 0.108 | 0.106 | % | 102 | 90.0 | - 110 | Acceptable | | |
| exo-THC | 1 | 0.0962 | 0.100 | % | 96.2 | 80.0 | - 120 | Acceptable | | |
| d9THC | 1 | 0.107 | 0.111 | % | 96.9 | 90.0 | - 110 | Acceptable | | |
| d8THC | 1 | 0.100 | 0.105 | % | 96.1 | 90.0 | - 110 | Acceptable | | |
| CBL | 1 | 0.0918 | 0.100 | % | 91.8 | 80.0 | - 120 | Acceptable | | |
| CBC | 1 | 0.0995 | 0.100 | % | 99.5 | 80.0 | - 120 | Acceptable | | |
| THCA | 1 | 0.0916 | 0.0891 | % | 103 | 90.0 | - 110 | Acceptable | | |
| CBCA | 1 | 0.0994 | 0.100 | % | 99.4 | 80.0 | - 120 | Acceptable | | |
| CBLA | 1 | 0.102 | 0.100 | % | 102 | 80.0 | - 120 | Acceptable | | |
| CBT | 1 | 0.0963 | 0.100 | % | 96.3 | 80.0 | - 120 | Acceptable | | |

| Method Blank | | | | | | |
|--------------|--|--------|-------|----------|------------|-------|
| Analyte | Result | LOQ | Units | Limits | Evaluation | Notes |
| CBDVA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBDV | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBE | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBDA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBGA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBG | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBD | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| THCV | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| d8THCV | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| THCVA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBN | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| exo-THC | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| d9THC | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| d8THC | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBL | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBC | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| THCA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBCA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBLA | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |
| CBT | <loq< td=""><td>0.0077</td><td>%</td><td>< 0.0077</td><td>Acceptable</td><td></td></loq<> | 0.0077 | % | < 0.0077 | Acceptable | |

Abbreviations

s ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

Units of Measure: % - Percent

Page 5 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 22-008818/D006.R000 |
|-----------------|---------------------|
| Report Date: | 08/02/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 07/26/22 12:43 |

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| | | | La | boratory | Quality Cor | ntrol Results | | | | |
|-------------------|--|--|-------|----------|-------------|---------------|------------|-------|--|--|
| J AOAC 2015 V98-6 | Batch ID: 2206386 | | | | | | | | | |
| Sample Duplicate | Sample ID: 22-008365-0003-01 | | | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes | | |
| CBDVA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBDV | 29.1 | 29.6 | 0.077 | % | 1.78 | < 20 | Acceptable | | | |
| CBE | 6.02 | 5.80 | 0.077 | % | 3.78 | < 20 | Acceptable | | | |
| CBDA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBGA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBG | 9.81 | 9.43 | 0.077 | % | 4.02 | < 20 | Acceptable | | | |
| CBD | 40.6 | 39.9 | 0.077 | % | 1.68 | < 20 | Acceptable | | | |
| THCV | 0.0907 | 0.0816 | 0.077 | % | 10.6 | < 20 | Acceptable | | | |
| d8THCV | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| THCVA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBN | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| exo-THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| d9THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| d8THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBL | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBC | 0.158 | 0.159 | 0.077 | % | 0.670 | < 20 | Acceptable | | | |
| THCA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBCA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBLA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |
| CBT | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | |

Abbreviations

ND - None Detected at or above MRL RPD - Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure:

Page 6 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





Report Number: 22-008818/D006.R000 **Report Date:** 08/02/2022 **ORELAP#:** OR100028 **Purchase Order: Received:** 07/26/22 12:43



Page 7 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





22-008818/D006.R000 **Report Number: Report Date:** 08/02/2022 **ORELAP#:** OR100028 **Purchase Order: Received:** 07/26/22 12:43

Explanation of QC Flag Comments:

| Code | Explanation |
|------|---|
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| В | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |

 www.columbialaboratories.com
 Page 8 of 8

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430

SD230329-008 page 1 of 2

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

sample 03DTST224_AMBER_D8 Distillate

DPharmLabs

Sample ID SD230329-008 (71349) Matrix Concentrate (Inhalable Cannabis Good)

Tested for The Hemp Collect Sampled -Received Mar 28, 2023 Analyses executed CAN+, RES, MIBIG, MTO, PES, HME, FVI

Reported Apr 05, 2023

Laboratory note: The estimated concentration of the unknown peak in the sample is 660% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC, (+)d8-THC is a different compound from the main (-)d8-THC cannobinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC and d9-THC is problematic for the scientific community as a whole. PhormLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be 94.56%.

CAN+ - Cannabinoids Analysis

Analyzed Apr 04, 2023 | Instrument HPLC-VWD | Method SOP-001 The expanded Uncertainty of the Cannabinoid analysis is approximately **#.806%** at the 95% Confidence Level

| Indy of many of the mark of the | The expanded offeer taining of the cannobiola analysis is approximately 2.000% at the 75% connactice zever | | | | |
|---|--|-------|------|-------|--------|
| Cannabidolic Acid (CBDA) 0.001 0.16 ND ND Cannabigerol Acid (CBGA) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabidol (CBD) 0.001 0.16 ND ND Cannabidol (CBN) 0.001 0.16 ND ND Cannabigoral (AS-THC) 0.002 0.16 ND ND Cannabigoral (AS-THC) 0.002 0.16 ND ND Cannabigoral (AS-THC) 0.002 0.16 ND ND Cannabigoral (CBC) 0.001 0.16 ND ND Cannabigoral (CBC) 0.002 0.16 ND ND Cannabigoral (CBC) 0.001 | Analyte | | | | |
| Cannabigerol Acid (CBGA) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigorol (CBG) 0.001 0.16 ND ND Cannabigorol (CBO) 0.001 0.16 ND ND Cannabinol (CBN) 0.001 0.16 ND ND Cannabinol (A9-THC) 0.003 0.16 UI UI AB-tetrahydrocannabinol (A9-THC) 0.002 0.16 ND ND Cannabicyclo (CBL) 0.002 0.16 ND ND Cannabinol (A9-THC) 0.002 0.16 ND ND Cannabinol (CBL) 0.002 0.16 ND ND Cannabinolic Acid (THCA) 0.001 0.16 ND ND Cannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa* 0.877 + A9THC) ND ND ND Total CBC (EBGa* 0.877 + CBB) <t< td=""><td>Cannabidivarin (CBDV)</td><td>0.039</td><td>0.16</td><td>ND</td><td>ND</td></t<> | Cannabidivarin (CBDV) | 0.039 | 0.16 | ND | ND |
| Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Tetrahydrocannabivorin (THCV) 0.001 0.16 ND ND Cannabilo (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocannabinol (Δ9-THC) 0.002 0.16 ND ND Cannabilo (CBL) 0.002 0.16 ND ND Cannabilo (THCA) 0.001 0.16 ND ND Cannabilo (THCA) 0.001 0.16 ND ND Tetrahydrocannabinol (AS-TT+ASTHC) ND ND ND Total THC (THCa*0.877 + Δ8THC) ND ND ND Total CBG (EBGa*0.877 + CB) ND ND< | Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabidi (CBD) 0.001 0.16 ND ND Tetrahydrocannabivarin (THCV) 0.001 0.16 ND ND Cannabidiol (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocannabinol (Δ8-THC) 0.004 0.16 94.56 945.60 Cannabidiol (CBL) 0.002 0.16 ND ND Cannabidoniol (Δ8-THC) 0.002 0.16 ND ND Cannabidol (CBL) 0.001 0.16 ND ND Cannabidol (CBL) 0.001 0.16 ND ND Total THC (THCa * 0.877 + Δ9THC + Δ | Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Tetrahydrocannabivarin (THCV) 0.001 0.16 ND ND Cannabinol (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocannabinol (Δ8-THC) 0.004 0.16 94.56 945.60 Cannabicyclol (CBL) 0.002 0.16 ND ND Cannabicyclol (CBL) 0.001 0.16 ND ND Cannabicyclol (CBL) 0.001 0.16 ND ND Cannabicyclol (CBL) 0.001 0.16 ND ND Total THC (THca 0.877 + Δ9THC + Δ8THC) ND ND ND Total CBC (CBBa 0.9.77 + CBD) ND ND ND Total CBC (CBGa 0.8.77 + CBG) <td>Cannabigerol (CBG)</td> <td>0.001</td> <td>0.16</td> <td>ND</td> <td>ND</td> | Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabinol (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 U1 U1 Δ8-tetrahydrocannabinol (Δ9-THC) 0.004 0.16 94.56 945.60 Cannabinol (Δ9-THC) 0.002 0.16 ND ND Δ8-tetrahydrocannabinol (Δ9-THC) 0.002 0.16 ND ND Cannabichomene (CBL) 0.002 0.16 ND ND Cannabichomene (CBC) 0.001 0.16 ND ND Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa*0.877 + Δ9THC) ND ND ND ND Total THC (THCa*0.877 + Δ9THC + Δ8THC) Y | Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| Tetrahydrocanabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocanabinol (Δ9-THC) 0.004 0.16 94.56 945.60 Canabicyclol (CBL) 0.002 0.16 ND ND Canabichromene (CBC) 0.002 0.16 ND ND Tetrahydrocanabinol (Ad-THCA) 0.001 0.16 ND ND Total THC (THCa ⁺ 0.877 + Δ9THC) ND ND ND Total THC (THCa ⁺ 0.877 + Δ9THC + Δ8THC) 94.56 945.60 ND Total CBD (CBDa ⁺ 0.877 + Δ9THC + Δ8THC) ND ND ND Total CBG (CBDa ⁺ 0.877 + CBG) ND ND ND | Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Ab-tetra/glarcannabinol (Ab-THC) 0.004 0.16 94.56 945.60 Cannabicyclol (CBL) 0.002 0.16 ND ND Cannabicyclol (CBC) 0.002 0.16 ND ND Tetra/glarcannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa * 0.877 + A9THC) ND ND ND Total CBD (CBDa* 0.877 + A9THC + A8THC) 94.56 94.56 Total CBD (CBDa* 0.877 + CBD) ND ND Total CBG (CBGa* 0.877 + CBG) ND ND | Cannabinol (CBN) | 0.001 | 0.16 | ND | ND |
| Cannabicyclol (CBL) 0.002 0.16 ND ND Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa ° 0.877 + 49THC) ND ND ND Total THC + 48THC (THCa ° 0.877 + 49THC + 48THC + 48T | Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | UI | UI |
| Cannabichromene (CBC) 0.002 0.16 ND ND Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa ^{0.0877 +} A9THc) ND ND ND Total THC + A8THC (THCa ^{0.0877 +} A9THc + A8THc) 94.56 945.60 Total CBC (BBGa ^{0.0877 +} CBD) ND ND Total CBC (CBGa ^{0.0877 +} CBC) ND ND | Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 94.56 | 945.60 |
| Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa * 0.877 + Δ9THc) ND ND ND Total THC + Δ8THC (THCa * 0.877 + Δ9THc + Δ8THc) 94.56 945.60 Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Cannabicyclol (CBL) | 0.002 | 0.16 | ND | ND |
| Total THC (THCa * 0.877 + Δ9THc) ND ND Total THC + Δ8THC (THCa * 0.877 + Δ9THc + Δ8THc) 94.56 945.60 Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Cannabichromene (CBC) | 0.002 | 0.16 | ND | ND |
| Total THC + A&THC (THCa * 0.877 + AØTHC + A&THC) 94.56 945.60 Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | ND | ND |
| Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Total THC (THCa * 0.877 + Δ9THC) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) ND ND | Total THC + Δ 8THC (THCa * 0.877 + Δ 9THC + Δ 8THC) | | | 94.56 | 945.60 |
| | Total CBD (CBDa * 0.877 + CBD) | | | ND | ND |
| Total Cannabinoids 94.56 945.60 | Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| | Total Cannabinoids | | | 94.56 | 945.60 |

HME - Heavy Metals Detection Analysis

Analyzed Apr 04, 2023 | Instrument ICP/MSMS | Method SOP-005

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|--------------|-------------|-------------|----------------|---------------|--------------|-------------|-------------|----------------|---------------|
| Arsenic (As) | 0.0002 | 0.0005 | ND | 0.2 | Cadmium (Cd) | 3.0e-05 | 0.0005 | ND | 0.2 |
| Mercury (Hg) | 1.0e-05 | 0.0001 | ND | 0.1 | Lead (Pb) | 1.0e-05 | 0.00125 | ND | 0.5 |

MIBIG - Microbial Testing Analysis

Analyzed Mar 31, 2023 | Instrument qPCR and/or Plating | Method SOP-007

| Analyte | Result CFU/g | Limit | Analyte | Result CFU/g | Limit |
|--|-----------------|---------------|---------------------|-----------------|---------------|
| Shiga toxin-producing Escherichia Coli | ND | ND per 1 gram | Salmonella spp. | ND | ND per 1 gram |
| Aspergillus fumigatus | ND | ND per 1 gram | Aspergillus flavus | ND | ND per 1 gram |
| Aspergillus niger | ND | ND per 1 gram | Aspergillus terreus | ND | ND per 1 gram |

MTO - Mycotoxin Testing Analysis

Analyzed Apr 04, 2023 | Instrument LC/MSMS | Method SOP-004

| Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg (ppb) | Limit ug/kg | Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg (ppb) | Limit ug/kg |
|--------------|--------------|--------------|-----------------------|----------------|------------------|--------------|--------------|-----------------------|----------------|
| Ochratoxin A | 5.0 | 20.0 | ND | 20 | Aflatoxin B1 | 2.5 | 5.0 | ND | - |
| Aflatoxin B2 | 2.5 | 5.0 | ND | - | Aflatoxin G1 | 2.5 | 5.0 | ND | - |
| Aflatoxin G2 | 2.5 | 5.0 | ND | - | Total Aflatoxins | 10.0 | 20.0 | ND | 20 |







Brandon Starr, Lab Manager Wed, 05 Apr 2023 10:13:00 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 "This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fall status is reported, that status is intended to be in accordance with federal, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fall evolution unless explicition unless expliciting, state or local lows and has been reported on the retrificate of analysis. Ressurement of uncertainty is available upon request.

Authorized Signature

Brandon Starr

SD230329-008 page 2 of 2

QA Testing

PES - Pesticides Screening Analysis

Analyzed Apr 04, 2023 | Instrument LC/MSMS GC/MSMS | Method SOP-003

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|-------------------------|-------------|-------------|----------------|---------------|-----------------------|-------------|-------------|----------------|---------------|
| Aldicarb | 0.0078 | 0.02 | ND | 0.0078 | Carbofuran | 0.01 | 0.02 | ND | 0.01 |
| Dimethoate | 0.01 | 0.02 | ND | 0.01 | Etofenprox | 0.02 | 0.1 | ND | 0.02 |
| Fenoxycarb | 0.01 | 0.02 | ND | 0.01 | Thiachloprid | 0.01 | 0.02 | ND | 0.01 |
| Daminozide | 0.01 | 0.03 | ND | 0.01 | Dichlorvos | 0.02 | 0.07 | ND | 0.02 |
| Imazalil | 0.02 | 0.07 | ND | 0.02 | Methiocarb | 0.01 | 0.02 | ND | 0.01 |
| Spiroxamine | 0.01 | 0.02 | ND | 0.01 | Coumaphos | 0.01 | 0.02 | ND | 0.01 |
| Fipronil | 0.01 | 0.1 | ND | 0.01 | Paclobutrazol | 0.01 | 0.03 | ND | 0.01 |
| Chlorpyrifos | 0.01 | 0.04 | ND | 0.01 | Ethoprophos (Prophos) | 0.01 | 0.02 | ND | 0.01 |
| Baygon (Propoxur) | 0.01 | 0.02 | ND | 0.01 | Chlordane | 0.04 | 0.1 | ND | 0.04 |
| Chlorfenapyr | 0.03 | 0.1 | ND | 0.03 | Methyl Parathion | 0.02 | 0.1 | ND | 0.02 |
| Mevinphos | 0.03 | 0.08 | ND | 0.03 | Abamectin | 0.03 | 0.08 | ND | 0.1 |
| Acephate | 0.02 | 0.05 | ND | 0.1 | Acetamiprid | 0.01 | 0.05 | ND | 0.1 |
| Azoxystrobin | 0.01 | 0.02 | ND | 0.1 | Bifenazate | 0.01 | 0.05 | ND | 0.1 |
| Bifenthrin | 0.02 | 0.35 | ND | 3 | Boscalid | 0.01 | 0.03 | ND | 0.1 |
| Carbaryl | 0.01 | 0.02 | ND | 0.5 | Chlorantraniliprole | 0.01 | 0.04 | ND | 10 |
| Clofentezine | 0.01 | 0.03 | ND | 0.1 | Diazinon | 0.01 | 0.02 | ND | 0.1 |
| Dimethomorph | 0.02 | 0.06 | ND | 2 | Etoxazole | 0.01 | 0.05 | ND | 0.1 |
| Fenpyroximate | 0.02 | 0.1 | ND | 0.1 | Flonicamid | 0.01 | 0.02 | ND | 0.1 |
| Fludioxonil | 0.01 | 0.05 | ND | 0.1 | Hexythiazox | 0.01 | 0.03 | ND | 0.1 |
| Imidacloprid | 0.01 | 0.05 | ND | 5 | Kresoxim-methyl | 0.01 | 0.03 | ND | 0.1 |
| Malathion | 0.01 | 0.05 | ND | 0.5 | Metalaxyl | 0.01 | 0.02 | ND | 2 |
| Methomyl | 0.02 | 0.05 | ND | 1 | Myclobutanil | 0.02 | 0.07 | ND | 0.1 |
| Naled | 0.01 | 0.02 | ND | 0.1 | Oxamyl | 0.01 | 0.02 | ND | 0.5 |
| Permethrin | 0.01 | 0.02 | ND | 0.5 | Phosmet | 0.01 | 0.02 | ND | 0.1 |
| Piperonyl Butoxide | 0.02 | 0.06 | ND | 3 | Propiconazole | 0.03 | 0.08 | ND | 0.1 |
| Prallethrin | 0.02 | 0.05 | ND | 0.1 | Pyrethrin | 0.05 | 0.41 | ND | 0.5 |
| Pyridaben | 0.02 | 0.07 | ND | 0.1 | Spinosad A | 0.01 | 0.05 | ND | 0.1 |
| Spinosad D | 0.01 | 0.05 | ND | 0.1 | Spiromesifen | 0.02 | 0.06 | ND | 0.1 |
| Spirotetramat | 0.01 | 0.02 | ND | 0.1 | Tebuconazole | 0.01 | 0.02 | ND | 0.1 |
| Thiamethoxam | 0.01 | 0.02 | ND | 5 | Trifloxystrobin | 0.01 | 0.02 | ND | 0.1 |
| Acequinocyl | 0.02 | 0.09 | ND | 0.1 | Captan | 0.01 | 0.02 | ND | 0.7 |
| Cypermethrin | 0.02 | 0.1 | ND | 1 | Cyfluthrin | 0.04 | 0.1 | ND | 2 |
| Fenhexamid | 0.02 | 0.07 | ND | 0.1 | Spinetoram J,L | 0.02 | 0.07 | ND | 0.1 |
| Pentachloronitrobenzene | 0.01 | 0.1 | ND | 0.1 | | | | | |

RES - Residual Solvents Testing Analysis

Analyzed Apr 04, 2023 | Instrument GC/FID with Headspace Analyzer | Method SOP-006

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|----------------------------|-------------|-------------|----------------|---------------|------------------------------|-------------|-------------|----------------|---------------|
| Propane (Prop) | 0.4 | 40.0 | ND | 5000.0 | Butane (But) | 0.4 | 40.0 | ND | 5000.0 |
| Methanol (Metha) | 0.4 | 40.0 | ND | 3000.0 | Ethylene Oxide (EthOx) | 0.4 | 0.8 | ND | 1.0 |
| Pentane (Pen) | 0.4 | 40.0 | ND | 5000.0 | Ethanol (Ethan) | 0.4 | 40.0 | ND | 5000.0 |
| Ethyl Ether (EthEt) | 0.4 | 40.0 | ND | 5000.0 | Acetone (Acet) | 0.4 | 40.0 | ND | 5000.0 |
| Isopropanol (2-Pro) | 0.4 | 40.0 | ND | 5000.0 | Acetonitrile (Acetonit) | 0.4 | 40.0 | ND | 410.0 |
| Methylene Chloride (MetCh) | 0.4 | 0.8 | 1.0 | 1.0 | Hexane (Hex) | 0.4 | 40.0 | ND | 290.0 |
| Ethyl Acetate (EthAc) | 0.4 | 40.0 | ND | 5000.0 | Chloroform (Clo) | 0.4 | 0.8 | ND | 1.0 |
| Benzene (Ben) | 0.4 | 0.8 | ND | 1.0 | 1-2-Dichloroethane (12-Dich) | 0.4 | 0.8 | ND | 1.0 |
| Heptane (Hep) | 0.4 | 40.0 | ND | 5000.0 | Trichloroethylene (TriClEth) | 0.4 | 0.8 | ND | 1.0 |
| Toluene (Toluene) | 0.4 | 40.0 | ND | 890.0 | Xylenes (Xyl) | 0.4 | 40.0 | ND | 2170.0 |

FVI - Filth & Foreign Material Inspection Analysis

Analyzed Mar 30, 2023 | Instrument Microscope | Method SOP-010

| Analyte / Limit | Result | Analyte / Limit | Result |
|--|--------|---|--------|
| >1/4 of the total sample area covered by sand, soil, cinders, or dirt | ND | > 1/4 of the total sample area covered by mold | ND |
| >1 insect fragment, 1 hair, or 1 count mammalian excreta per 3g | ND | > 1/4 of the total sample area covered by an imbedded foreign material | ND |

UI Not Identified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Wed, 05 Apr 2023 10:13:00 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "os received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evolution unless explicitude, state or local laws which are required by the nor Pass/Fail status is reported, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is available uncertainty is ava